Drug
AZD9833 clinical trials
Also written AZD9833 and Camizestrant.
- studies test it
- 19
- open now
- 6
- in phase 3
- 6
- first study started
- 2018
Keep track of what changes. Save the AZD9833 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
AstraZeneca (17) · University Health Network, Toronto (1) · MedSIR (1)
Often tested with
Tested in the same studies.
Ribociclib (4) · Palbociclib (3) · Everolimus (2) · Abemaciclib (2) · Anastrozole (2) · Midazolam (2) · Capivasertib (1) · Carbamazepine (1)
Studies
Open first, then newest update. How each study uses AZD9833 is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT07647328Written as Camizestrant
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951Written as Camizestrant
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingPhase 2AstraZenecaNCT07427394Written as Camizestrant
- Phase II Study of CAmizestrant in Resectable Endometrial AdenocarcinomaNot yet recruitingPhase 2University Health Network, TorontoNCT07840443Written as Camizestrant
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Camizestrant
- Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingPhase 2MedSIRNCT07195227Written as Camizestrant
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingPhase 3AstraZenecaNCT04711252Written as AZD9833
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934Written as AZD9833
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingPhase 2AstraZenecaNCT04214288Written as AZD9833
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587Written as AZD9833
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557Written as Camizestrant
- A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsCompletedPhase 1AstraZenecaNCT06547164Written as Camizestrant
- A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerCompletedPhase 1AstraZenecaNCT04541433Written as AZD9833
- Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsCompletedPhase 1AstraZenecaNCT05790304Written as Camizestrant
- A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast CancerCompletedPhase 2AstraZenecaNCT04588298Written as AZD9833
- AZD9833 China PK StudyCompletedPhase 1AstraZenecaNCT04818632Written as AZD9833
- Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersCompletedPhase 1AstraZenecaNCT05438303Written as AZD9833
- A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleCompletedPhase 1AstraZenecaNCT05551897Written as Camizestrant
- A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833CompletedPhase 1AstraZenecaNCT04546347Written as AZD9833 film-coated tablet A Dose 1
Given in every arm · 2 — AZD9833 is usual care beside what is tested
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2AstraZenecaNCT06188520Written as Camizestrant
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingPhase 1/2AstraZenecaNCT04644068Written as Camizestrant
Codes
What other systems call AZD9833 · ClinicalTrials.gg INT001822
- MeSH (NLM) C000722187AZD9833One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722187 | AZD9833 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.